Last reviewed · How we verify
Taclonex
At a glance
| Generic name | Taclonex |
|---|---|
| Also known as | Calcipotriene, betamethasone, Calcipotriene and Betamethasone Dipropionate, Taclonex® Ointment, (calcipotriene 0.005% betamethasone dipropionate 0.064%), Taclonex Scalp® |
| Sponsor | Tolmar Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (PHASE3)
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris (PHASE2)
- Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (PHASE2)
- Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis (PHASE2)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taclonex CI brief — competitive landscape report
- Taclonex updates RSS · CI watch RSS
- Tolmar Inc. portfolio CI